Artikel Jurnal

The Efectiveness of Atorvastatin for The Prevention of Deep Vein Thrombosis in Cancer Patients Undergoing Chemotherapy

---

Background Deep vein thrombosis (DVT) is a common complication in cancer. Although thromboprophylaxis in
cancer patients is recommended by the guidelines, clinicians’ use of thromboprophylaxis remains limited due to cost,
bleeding complications, and reluctance to give injectable anticoagulants. Infammation plays essential roles in the
pathogenesis of cancer-associated thrombosis. Owing to its ability to decrease proinfammatory cytokines, statins
have anti-infammatory properties. Thus, statins can be possibly utilized as thromboprophylaxis therapy in cancer
patients undergoing chemotherapy.
Objective To compare the efectiveness of atorvastatin and rivaroxaban for DVT prevention in high-risk thrombosis
patients with cancer undergoing chemotherapy.
Methods Double-blind, randomized controlled trial involving cancer patients with high-risk of thrombosis undergoing chemotherapy. We randomly assigned patients without deep-vein thrombosis at screening to receive atorvastatin 20 mg or rivaroxaban 10 mg daily for up to 90 days. Doppler ultrasonography was performed 90 days following
chemotherapy to diagnose DVT. Average cost-efectiveness analysis was performed to analyze the cost of atorvastatin
compared to rivaroxaban.
Results Of the eighty six patients who underwent randomization, primary efcacy end point was observed in 1 of 42
patients (2.3%) in the atorvastatin group and in 1 of 44 (2.2%) in the rivaroxaban group (Odds Ratio [OR], 0.953; 95%
confdence interval [CI], 0.240 to 3.971; p=1.000). There was a signifcant diference in the incidence of major bleeding, 2 of 42 patients (4.8%) in the atorvastatin group and 12 of 44 (27.3%) in the rivaroxaban group (OR, 0.257; 95% CI,
0.07 to 0.94; p=0.007). The average cost-efectiveness ratio of using atorvastatin was lower than that of rivaroxaban.
Conclusion Atorvastatin did not difer signifcantly from rivaroxaban in reducing the incidence of DVT, lower bleeding risk, and cost-efectiveness for thromboprophylaxis in high-risk thrombosis patients with cancer undergoing
chemotherapy. The presence of limited statistical power and wide confdence intervals in this study needs further
study to strengthen the efcacy of atorvastatin as DVT prophylaxis in cancer patients.

---

Availability

Detail Information

Series Title

-

Call Number

616.15 Bud t

Publisher

: Thrombosis Journal., 2023

Collation

-

Language

English

ISBN/ISSN

1477-9560

Classification

616.15

Content Type

text

Media Type

other

Carrier Type

other (computer)

Edition

-

Subject(s)

Atorvastatin
Venous Thrombosis
Neoplasms

Specific Detail Info

15 hlm.

Statement of Responsibility

Budi Setiawan

Viewer

92

Other Information

Tanggal Pelaksanaan - Dari

2024-12-30

Tanggal Pelaksanaan - Sampai

2024-12-30

Akreditasi

Tidak

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment